Sally D. Woodhouse

Senior Advisor


  • Boston


Sally Woodhouse consults on pharmaceutical and healthcare matters involving antitrust, product misrepresentation, intellectual property, False Claims Act, breach of contract, and securities fraud allegations. Dr. Woodhouse is a former cohead of Cornerstone Research’s life sciences practice.

Life sciences

Dr. Woodhouse’s experience in life sciences antitrust matters includes assessing the appropriateness of class certification, analyzing relevant markets and competitive effects, and estimating damages. These cases have involved allegations of delayed or suppressed generic competition related to reverse payment settlements, product hopping, risk evaluation and mitigation strategy (REMS) programs, and noncompete agreements.

Dr. Woodhouse has also analyzed:

  • Pharmaceutical pricing practices in the context of average wholesale price (AWP) litigation
  • Commercial reasonableness of drug development and commercialization efforts in breach of contract matters
  • Damages, commercial success, and irreparable harm in pharmaceutical patent infringement matters
  • Damages and class certification issues in pharmaceutical improper marketing matters
  • Company clinical trial protocols, analyses of clinical trial data, and other biostatistics issues arising in securities and product misrepresentation matters
  • Competitive effects of a merger of biopharmaceutical companies, including the ability and incentives of the combined entity to employ bundled rebates to foreclose competition

Dr. Woodhouse has consulted on healthcare matters involving health insurance companies, physicians groups, hospitals, and pharmacies, including retail, specialty, and long-term care pharmacies. Her work on these matters has included assessing merger effects, monopolization claims, and reimbursement disputes, among other topics.

Other litigation

Dr. Woodhouse has consulted on cases in a number of other industries, including automotive, consumer products, financial institutions, and high tech.

Professional Affiliations

Value Drug Company v. Takeda Pharmaceuticals U.S.A. Inc. et al.


In re Novartis and Par Antitrust Litigation


Amgen Inc.’s Acquisition of Horizon Therapeutics plc


In re HIV Antitrust Litigation


Pro Bono: Cornerstone Research Supports Efforts to Protect Voting Rights

Press Release

Boston Globe Article Features Cornerstone Research


Alleged Failure to Disclose Drug Safety Issues


ICC Arbitration Involving Commercially Reasonable Efforts to Develop and Commercialize a Drug

  • “Evaluating Reverse Payment Settlements after Actavis,” Law360, June 2013
  • “Does Generic Entry Always Increase Consumer Welfare?,” Food and Drug Law Journal, 2012
  • “Analyzing Competition in the Pharmaceutical Industry,” Economics Committee Newsletter, American Bar Association Section of Antitrust Law, Spring 2008
  • “Recent Antitrust Developments in Health Care and Pharmaceuticals,” Health Care and Pharmaceuticals Committee, American Bar Association Section of Antitrust Law, 17 May 2016
  • “Hot Topics in Healthcare Anti-Kickback and False Claims Act Cases,” Health Care and Pharmaceuticals Committee, American Bar Association Section of Antitrust Law, 13 January 2016
  • “Seeing the Big Picture in Life Sciences Law: The Substantive Legal Developments That Women Leaders Must Know,” Women Leaders in Life Sciences Law, 23 July 2015
  • “Current Issues in Pharmaceuticals Intellectual Property and Antitrust Litigation,” American Bar Association Section of Intellectual Property Law, 9 June 2015